Medical management of frontotemporal dementia.
There are no Food and Drug Administration (FDA)-approved medications for the medical management of frontotemporal dementia and its related disorders, so all management recommendations are necessarily off-label and borrowed from experience with Alzheimer's disease, psychiatric disease, and related medical illnesses. Six areas of pharmacotherapeutic consideration are prevention (primary and secondary), intellectual decline, behavioral disorders (such as depression, anxiety, and psychosis), sleep disorders, frequently associated disorders (including motor neuron disease), and abrupt decline. In addition to pharmacotherapy, important lifestyle issues confronting the clinician include driving cessation, securing any weapons maintained at home, assisted living, and caregiver burnout.
Caselli
Richard J
RJ
Department of Neurology, Mayo Clinic and Arizona Alzheimer's Disease Consortium, Scottsdale, Arizona 85259, USA. caselli.richard@mayo.edu
Yaari
Roy
R
D000368:Aged; D002491:Central Nervous System Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015897:Comorbidity; D003704:Dementia / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control / Q000523:psychology; D018450:Disease Progression; D017277:Drug Approval; D006801:Humans; D008019:Life Style; D011322:Primary Prevention; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D002491:Central Nervous System Agents; D011619:Psychotropic Drugs